Literature DB >> 18584300

Quantification of PSA mRNA levels in peripheral blood of patients with localized prostate adenocarcinoma before, during, and after radical prostatectomy by quantitative real-time PCR (qRT-PCR).

Nadir Kalfazade1, Ahmet M Kuskucu, Serdar Karadag, Selcuk Sahin, Bekir Aras, Kenan Midilli, Gülden Yilmaz, Ali I Tasci.   

Abstract

OBJECTIVE: To evaluate the clinical value of detected prostate-specific antigen (PSA) mRNA expression levels in circulating cells in patients with prostate cancer by quantitative real-time polymerase chain reaction (qRT-PCR) and to determine the effect of surgical manipulation on hematogenous dissemination.
METHODS: Blood samples before, during, and after (24 h) surgery were obtained from 34 patients with prostate cancer who underwent radical prostatectomy for detecting PSA mRNA expression levels. PSA mRNA expression levels, PSA levels, and Gleason scores were then compared.
RESULTS: PSA mRNA expression levels were detected in 14 of 34 (41%) patients, and biochemical recurrence of blood PSA was observed in 6 of 34 (17%) patients. Differences of PSA mRNA expression levels in pre-, per-, and postoperative periods were statistically significant (P < 0.001) and differences of PSA mRNA expression levels in pre- and peroperative samples (P < 0.008), pre- and postoperative samples (P < 0.031), and per- and postoperative samples (P < 0.001) were also statistically meaningful. There was significant relationship between the detectable PSA mRNA expression levels in preoperative samples and biochemical recurrence of blood PSA levels. We demonstrated that surgical manipulation had no effect on biochemical recurrence of blood PSA. We also showed that there was significant correlation between high Gleason score and the detectable PSA mRNA expression levels (P < 0.027).
CONCLUSIONS: Our results suggest that highly detectable PSA mRNA expression levels in preoperative samples seem to be a significant predictable factor for prostate cancer recurrence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18584300     DOI: 10.1007/s11255-008-9416-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  31 in total

1.  Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.

Authors:  B Straub; M Müller; H Krause; M Schrader; C Goessl; R Heicappell; K Miller
Journal:  Urology       Date:  2001-11       Impact factor: 2.649

2.  Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.

Authors:  T Okegawa; H Noda; M Kato; A Miyata; K Nutahara; E Higashihara
Journal:  Prostate       Date:  2000-08-01       Impact factor: 4.104

3.  Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.

Authors:  C L Gao; S Maheshwari; R C Dean; L Tatum; R Mooneyhan; R R Connelly; D G McLeod; S Srivastava; J W Moul
Journal:  Urology       Date:  1999-04       Impact factor: 2.649

4.  Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy.

Authors:  A de la Taille; C A Olsson; R Buttyan; M C Benson; E Bagiella; Y Cao; M Burchardt; D K Chopin; A E Katz
Journal:  Int J Cancer       Date:  1999-08-20       Impact factor: 7.396

Review 5.  RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview.

Authors:  A Zippelius; K Pantel
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

6.  Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.

Authors:  Hideaki Miyake; Toshifumi Kurahashi; Isao Hara; Atsushi Takenaka; Masato Fujisawa
Journal:  BJU Int       Date:  2006-11-28       Impact factor: 5.588

7.  Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction.

Authors:  T Deguchi; T Doi; H Ehara; S Ito; Y Takahashi; Y Nishino; S Fujihiro; T Kawamura; H Komeda; M Horie
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  Quantitative PSA RT-PCR for preoperative staging of prostate cancer.

Authors:  Ralf Kurek; Alice Ylikoski; Heiner Renneberg; Lutz Konrad; Gerd Aumüller; Sandra J Roddiger; Nikolaos Zamboglou; Ulf W Tunn; Hans Lilja
Journal:  Prostate       Date:  2003-09-01       Impact factor: 4.104

9.  Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.

Authors:  C A Olsson; G M de Vries; A J Raffo; M C Benson; K O'Toole; Y Cao; R E Buttyan; A E Katz
Journal:  J Urol       Date:  1996-05       Impact factor: 7.450

10.  Quantitative real-time rt-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients.

Authors:  Bernd Straub; Markus Müller; Hans Krause; Mark Schrader; Kurt Miller
Journal:  Oncology       Date:  2003       Impact factor: 2.935

View more
  2 in total

1.  Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer.

Authors:  Hyungseok Cho; Cheol Kyu Oh; Jiwon Cha; Jae Il Chung; Seok-Soo Byun; Sung Kyu Hong; Jae-Seung Chung; Ki-Ho Han
Journal:  Prostate Int       Date:  2022-01-10

2.  Isolation and characterization of circulating tumor cells in prostate cancer.

Authors:  Elan Diamond; Guang Yu Lee; Naveed H Akhtar; Brian J Kirby; Paraskevi Giannakakou; Scott T Tagawa; David M Nanus
Journal:  Front Oncol       Date:  2012-10-11       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.